{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:28:32Z","timestamp":1783117712518,"version":"3.54.6"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Since the World Health Organization declared a global pandemic due to the novel coronavirus disease2019, there have been targeted efforts to establish management modalities. Hydroxychloroquine has been suggested as a possible treatment; however, it is associated with multiple adverse reactions. We report a rare case of a patient with acute generalized exanthematous pustulosis with Stevens-Johnson syndrome due to hydroxychloroquine. Acute generalized exanthematous pustulosis is characterized by acute onset of a generalized rash that is pustular and erosive in nature, affecting limbs; trunk; face; and, less often, mucosal membranes. Although rare, it is important to be mindful of this side effect because the diagnosis is often delayed, and the disease has the potential to be life-threatening.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>A 68-year-old American woman presented to our hospital with a painful, rapidly spreading rash. Its morphologic features included erythema multiforme\u2013like lesions with extensive skin sloughing in various regions of the head, neck, and trunk and mucosal involvement. Her Nikolsky sign was negative, and she had no evidence of lesions on areas of skin trauma. Four weeks prior, she had been initiated on hydroxychloroquine for a presumed diagnosis of cutaneous sarcoidosis. Three punch biopsies of the head and neck area revealed subcorneal pustules consistent with acute generalized exanthematous pustulosis. Treatment began with high doses of methylprednisolone, leading to only minimal improvement of existing areas and ongoing spread to new areas. Treatment with intravenous immunoglobulin was initiated, at which point disease stability was achieved. The patient\u2019s rash ultimately resolved, as did her cutaneous pain and pruritus.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Among many potential adverse reactions involving hydroxychloroquine, cutaneous side effects are varied and can lead to significant morbidity or even death. The drug is currently being investigated in a multitude of trials for coronavirus disease2019 treatment, prevention, and prophylaxis after exposure to severe acute respiratory syndrome coronavirus 2. Acute generalized exanthematous pustulosis is a rare side effect of hydroxychloroquine, and even fewer cases demonstrate histologic evidence of acute generalized exanthematous pustulosis while clinically presenting with Stevens-Johnson syndrome. Patients who develop Stevens-Johnson syndrome\/toxic epidermal necrolysis require best supportive care with aggressive fluid and electrolyte replacement and prevention of further breakdown of the skin barrier. With the potential of widespread hydroxychloroquine use, it is important that providers be aware of its potential severe adverse drug reactions.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13256-020-02504-8","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:05:02Z","timestamp":1604361902000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a\u00a0case report"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1407-3732","authenticated-orcid":false,"given":"Ivorie","family":"Coleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumir","family":"Brahmbhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,3]]},"reference":[{"issue":"4","key":"2504_CR1","doi-asserted-by":"publisher","first-page":"105945","DOI":"10.1016\/j.ijantimicag.2020.105945","volume":"55","author":"Z Sahraei","year":"2020","unstructured":"Sahraei Z, Shabani M, Shokouhi S, Saffaei A. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents. 2020;55(4):105945.","journal-title":"Int J Antimicrob Agents"},{"key":"2504_CR2","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10787-015-0239-y","volume":"23","author":"K Rainsford","year":"2015","unstructured":"Rainsford K, Parke AL, Clifford-Rashotte M, Kean W. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015;23:231\u201369.","journal-title":"Inflammopharmacology"},{"issue":"3","key":"2504_CR3","doi-asserted-by":"publisher","first-page":"105923","DOI":"10.1016\/j.ijantimicag.2020.105923","volume":"55","author":"P Colson","year":"2020","unstructured":"Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents. 2020;55(3):105923.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"2504_CR4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.mcna.2010.04.004","volume":"94","author":"T Harr","year":"2010","unstructured":"Harr T, French LE. Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome. Med Clin North Am. 2010;94(4):727.","journal-title":"Med Clin North Am"},{"issue":"6","key":"2504_CR5","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1161\/CIR.0000000000000426","volume":"134","author":"RL Page 2nd","year":"2016","unstructured":"Page RL 2nd, O\u2019Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association [published correction appears in Circulation. 2016;134(12):e261]. Circulation. 2016;134(6):e32\u201369. \nhttps:\/\/doi.org\/10.1161\/CIR.0000000000000426\n\n.","journal-title":"Circulation."},{"issue":"9105","key":"2504_CR6","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(05)78925-X","volume":"351","author":"JA Block","year":"1998","unstructured":"Block JA. Hydroxychloroquine and retinal safety. Lancet. 1998;351(9105):771. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(05)78925-X\n\n.","journal-title":"Lancet."},{"issue":"12","key":"2504_CR7","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1002\/ccr3.1811","volume":"6","author":"F Mohaghegh","year":"2018","unstructured":"Mohaghegh F, Jelvan M, Rajabi P. A case of prolonged generalized exanthematous pustulosis caused by hydroxychloroquine\u2014literature review. Clin Case Rep. 2018;6(12):2391\u20135.","journal-title":"Clin Case Rep"},{"key":"2504_CR8","unstructured":"Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19. ClinicalTrials.gov identifier: NCT04261517. \nhttps:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04261517?term=hydroxychloroquine&cond=Coronavirus&draw=1&rank=6\n\n. Accessed 25 Mar 2020."},{"key":"2504_CR9","unstructured":"Chloroquine\/Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting (COPCOV). ClinicalTrials.gov identifier: NCT04303507. \nhttps:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04303507?term=hydroxychloroquine&cond=Coronavirus&draw=2&rank=1\n\n. Accessed 25 Mar 2020."},{"key":"2504_CR10","unstructured":"Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19). \nClinicalTrials.gov\n\n identifier: NCT04318444. \nhttps:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04318444?term=COVID-19&cond=hydroxychloroquine&draw=2&rank=1\n\n. Accessed 25 Mar 2020."},{"key":"2504_CR11","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1097\/BCR.0b013e31818ba0d3","volume":"29","author":"B Pomahac","year":"2008","unstructured":"Pomahac B, Lim J, Liu A. A case report of generalized pustulosis with systemic manifestations requiring burn intensive care unit admission. J Burn Care Res. 2008;29:1004\u20138.","journal-title":"J Burn Care Res"},{"key":"2504_CR12","first-page":"212","volume":"97","author":"KC Pearson","year":"2016","unstructured":"Pearson KC, Morrell DS, Runge SR, Jolly P. Prolonged pustular eruption from hydroxychloroquine: an unusual case of acute generalized exanthematous pustulosis. Cutis. 2016;97:212\u20136.","journal-title":"Cutis"},{"key":"2504_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2147\/JIR.S160964","volume":"11","author":"QX Ng","year":"2018","unstructured":"Ng QX, Deyn MLZQD, Venkatanarayanan N, Ho CYX, Yeo WS. A meta-analysis of cyclosporine treatment for Stevens-Johnson syndrome\/toxic epidermal necrolysis. J Inflamm Res. 2018;11:135\u201342.","journal-title":"J Inflamm Res"},{"issue":"8","key":"2504_CR14","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.3390\/ijms17081214","volume":"17","author":"L Feldmeyer","year":"2016","unstructured":"Feldmeyer L, Heidemeyer K, Yawalkar N. Acute generalized exanthematous pustulosis: pathogenesis, genetic background, clinical variants and therapy. Int J Mol Sci. 2016;17(8):1214.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2504_CR15","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/j.1365-2133.2007.08156.x","volume":"157","author":"A Sidoroff","year":"2007","unstructured":"Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)\u2014results of a multinational case-control study (EuroSCAR). Br J Dermatol. 2007;157(5):989\u201396.","journal-title":"Br J Dermatol"},{"key":"2504_CR16","unstructured":"WHO Director-General\u2019s opening remarks at the media briefing on COVID-19 - 25 May 2020. \nhttps:\/\/www.who.int\/dg\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---25-may-2020\n\n."},{"key":"2504_CR17","unstructured":"WHO Director-General\u2019s opening remarks at the media briefing on COVID-19 - 3 June 2020. \nhttps:\/\/www.who.int\/dg\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---03-June-2020\n\n."}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-02504-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13256-020-02504-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-02504-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:24:23Z","timestamp":1604363063000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-020-02504-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,3]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2504"],"URL":"https:\/\/doi.org\/10.1186\/s13256-020-02504-8","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,3]]},"assertion":[{"value":"20 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the fundamental principles of the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"210"}}